3 Houston innovators to know this week

who's who

This week's innovators to know roundup includes Patrick Jankowski of the Greater Houston Partnership, Deanea LeFlore of The Ion, and Dr. Mehdi Razavi of the Texas Heart Institute. Photos courtesy

Editor's note: In this week's Monday roundup of Houston innovators, I'm introducing you to three innovators across the city — from the Greater Houston Partnership, The Ion, and Texas Heart Institute.

Patrick Jankowski, senior vice president of research

The Greater Houston Partnership hosted its annual economic outlook event online this week. Photo courtesy of the GHP

At the GHP's annual economic outlook, Patrick Jankowski, senior vice president of research, predicts that 2021 will be a "bipolar year." The first and second halves of the year are going to look different, Jankowski says, it's just a matter of how different at this point. In addition to the vaccine and COVID case numbers, the things the GHP as well as Houston businesses are watching is the new Biden Administration.

"We won't see any significant growth in the economy until we get to the second half of the year," he says. Read more.

Deanea LeFlore, director of partnerships at The Ion

Deanea LeFlore, director of partnerships at The Ion, joins this week's episode of the Houston Innovators Podcast. Photo courtesy of Station Houston

Houston is just a few months away from being able to walk into The Ion, and the organization's director of partnerships, Deanea LeFlore, hopes that when that happens, they are entering a innovation hub reflective of the city.

"I think that when people walk into The Ion, what's personally important to me, is that it looks like Houston so that you see yourself reflected in the people in the building as well as the programming," LeFlore says. "That's my biggest hope and aspiration, and I believe we are well on track to be able to deliver on exactly that."

LeFlore shares more on what she's been working on — from online programming to growing partnerships at The Ion. Listen to the podcast and read more.

Dr. Mehdi Razavi, director of Electrophysiology Clinical Research & Innovations at the Texas Heart Institute

A medical device coming out of the Texas Heart Institute has been recognized for its innovation. Photo via THI

A new technology out of Houston's Texas Heart Institute's was named the top future medical product design worldwide last month as part of the annual Create the Future Design contest. The med device, which allows for pain-free defibrillation, is being developed by THI's Electrophysiology Clinical Research & Innovations team in conjunction with scientists at Rice University and UCLA, the technology allows doctors to place up to 12 tiny nodes around the heart to pace and defibrillate the heart without using a shock.

The technology will be most useful for atrial fibrillation and ventricular fibrillation, which can lead to sudden death, stroke, and congestive heart failure, according to Dr. Mehdi Razavi, the head investigator on this project and leader of the THI team.

"It's extremely painful. It's like someone takes a two by four and just pounds you from the inside in the chest, or a horse kicking you in the chest," Razavi says. He went on to add: "I have actually one patient who was a Vietnam veteran. He said nothing that he faced in battle was as disconcerting—not just because of the pain, but the fact that you don't know when the pain is when the shock is about to happen. That anxiety is just overwhelming." Read more.

A medical device coming out of the Texas Heart Institute has been recognized for its innovation. Photo via THI

Houston innovation team wins global award for painless heart technology

heart of gold

Houston's Texas Heart Institute's pain-free defibrillation technology was named the top future medical product design worldwide last month as part of the annual Create the Future Design contest.

The tiny technology aims to change the way cardiac arrhythmias are managed and remove the often traumatizing pain associated with their treatment. Developed by THI's Electrophysiology Clinical Research & Innovations team in conjunction with scientists at Rice University and UCLA, the technology allows doctors to place up to 12 tiny nodes around the heart to pace and defibrillate the heart without using a shock.

The technology will be most useful for atrial fibrillation and ventricular fibrillation, which can lead to sudden death, stroke, and congestive heart failure, according to Dr. Mehdi Razavi, the head investigator on this project and leader of the THI team. Razavi says winning the award "speaks to the need" of a new solution in the field as the shocks associated with traditional implantable cardioverter-defibrillators, or ICDs, can cause severe PTSD among patients.

"It's extremely painful. It's like someone takes a two by four and just pounds you from the inside in the chest, or a horse kicking you in the chest," Razavi says. He went on to add: "I have actually one patient who was a Vietnam veteran. He said nothing that he faced in battle was as disconcerting—not just because of the pain, but the fact that you don't know when the pain is when the shock is about to happen. That anxiety is just overwhelming."

Instead of shocking the patient's heart in a central location, the nodes spread energy needed to pace the heart at the correct rate throughout the muscle based on their location. This dilutes the feeling of a sudden jolt, and Razavi says, defibrillation using his technology could go unnoticed in patients.

In addition to this game-changing possibility, the new technology is physically safer in many ways, too. The miniaturized battery-less pacing system is free of traditional wires that send electrical pulses to the heart, known as leads. These leads can dislodge and fracture within the body and can cause infection.

The technology's wireless and miniature nature also allows doctors to better access regions of the heart that currently are difficult to reach with bulkier ICDs. Each node can be individually programmed and can stimulate different regions of the heart in different ways, as well.

A cross disciplinary team developed the device. Aydin Babakhani, an associate professor in physical and wave electronics at UCLA first developed the nodes to stimulate electricity for non-medical purposes. Behnaam Aazhang, the J.S. Abercrombie Professor of Electrical and Computer Engineering and the Director of the Rice Neuroengineering Initiative, first introduced Razavi to Babakhani, and the trio worked together to bring the technology to the medical arena, along with about 15 to 20 other medical professionals and students.

The team at Rice is continuing to develop the hardware for clinical use. And studies on the use of defibrillation through these nodes across the heart are being conducted out to the Texas Heart Institute's research lab. Razavi and his team are currently conducting preclinical studies on the new form of treatment and aims to roll it out for clinical use in the next three to five years.

From Houston inventors being recognized to Chevron's latest investment, here's what innovation news you need to know. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Chevron makes another investment, Houston researchers nationally recognized, and more innovation news

Short Stories

Houston's innovation news hasn't quite slowed yet for the holidays. This most recent news roundup includes lots of money raised, a new contract for a Houston startup, innovators recognized and more.

For more daily innovation news, subscribe to InnovationMap's newsletter, which goes out every weekday at 7 am.

Chevron Technology Ventures invests in Texas company

Courtesy of CTV

Houston-based Chevron Technology Ventures has contributed to Austin-based motor tech company Infinitum Electric's $12.5 million Series B round of financing. New Mexico-based Cottonwood Technology Fund and includes participation AJAX Strategies and other individual investors.

The company plans to use the funds to build out its research and development, engineering, supply chain, and production teams.

"Infinitum's mission aligns well with our goals for the Future Energy Fund," says Barbara Burger, president of CTV, in a release. "The purpose of the Future Energy Fund is to invest in breakthrough energy technologies that reflect Chevron's commitment to lower emission energy sources and that are integral to low-carbon and efficient value chains."

4 Houston researchers named fellows of the National Academy of Inventors

ideas

Getty Images

The National Academy of Inventors named 168 academic innovators to NAI Fellow status — and four conduct their research right here in Houston. The program "highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society," reads the news release.

The four Houston inventors and their institutions are as follows:

List ranks Houston's fastest growing companies

Chart via Grojo.com

Growjo named the 100 fastest-growing companies in Houston for 2019, and, while the study notes the city's large oil and gas and medical industries, also acknowledges its growing tech and software scene. The companies were selected by a myriad of factors.

"Our algorithm is based on multiple datasets including employee growth, estimated revenue growth, valuations, quality and quantity of funding, hiring announcements, current job openings, leadership team announcements, and numerous other growth triggers," reads the website.

The top five companies on the list are:

  1. Midcoast Energy, which has 183 employees and a 17 percent employee growth rate.
  2. ibüümerang, which has 528 employees, and a 633 percent employee growth rate.
  3. Arion, which has 136 employees and a 216 percent employee growth rate.
  4. GoExpedi, which as 59 employees and a 119 percent employee growth rate.
  5. Code Ninjas, which has 338 employees and a 63 percent employee growth rate.

For the full list, visit Growjo.com.

TMCx company wins awards 

Image via abilitechmedical.com

Abilitech Medical, which recently completed the TMCx program, has taken home some wins in Minnesota, where it's based. The company was named named among the state's topmed tech companies by the Minnesota High Tech Association at the 2019 TEKNE awards and 2019, as well as the grand prize winner and top woman-led business by the University of Minnesota's business school at its 2019 Minnesota Cup competition.

The medical device company's technology includes the Abilitech™ Assist, which assists patients with Multiple Sclerosis, rehabilitating from stoke, or other conditions with eating, drinking, and using a computer.

"We've met so many people whose lives will be changed with this innovation," says CEO and founder Angie Conley in a news release. "Through the Texas Medical Center accelerator, we met Dr. Hany Samir who championed our upcoming stroke study."

Samir is a cardiac anesthesiologist at Houston Methodist. He lost his ability to work and perform simple daily functions after a stroke debilitated his left arm.

"I'm unable to practice the medicine I love. I want to hold my wife again with two hands and enjoy dinner with her, without having her cut my food. I want to have a cup of coffee without asking for help," says Samir in the release. "Regaining function in my arm will restore my life."

Pandata Tech receives Department of Defense contract

Photo courtesy of Pandata Tech

Houston-based ​Pandata Tech secured a contract with the United States Department of Defense from the Rapid Sustainment Office of the the United States Air Force last month. The Phase II contract will allow the company to work with Joint Base Elmendorf-Richardson in Alaska to develop a scalable data quality platform.

The access to data will aid in natural disasters, per the release. The goal of the contract would be for a Phase III contract and an opportunity to scale the technology into other branches of military. The company also had a Phase I contract signed in August before securing the Phase II in November.

"Pandata Tech's proprietary DQM software was built during a development partnership with one of the world's largest offshore drilling companies. Because the technology was tested and built with offshore drilling data, the shift to aircraft carriers would be smooth," explains Gustavo Sanchez, co-founder of Pandata Tech, in a news release.

Houston company receives Department of Energy funding

Photo via aerominepower.com

The U.S. Department of Energy's National Renewable Energy Laboratory — with funding from the DOE's Office of Energy Efficiency and Renewable Energy Wind Energy Technologies Office — selected a Houston company for its Competitiveness Improvement Project.

Westergaard Solutions, founded by Houstonian Carsten Westergaard, was named among the 2019 CIP Awardees. Among the company's assets is AeroMine, which competed in the most recent Houston cohort in MassChallenge Texas. The company "will implement an innovative building-integrated wind generation concept with no external moving parts, moving from a preliminary conceptual design to a pre-production prototype design that is ready for testing," according to the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice research breakthrough paves the way for advanced disease therapies

study up

Bioengineers at Rice University have developed a “new construction kit” for building custom sense-and-respond circuits in human cells, representing a major breakthrough in the field of synthetic biology, which could "revolutionize" autoimmune disease and cancer therapeutics.

In a study published in the journal Science, the team focused on phosphorylation, a cellular process in the body in which a phosphate group is added to a protein, signaling a response. In multicellular organisms, phosphorylation-based signaling can involve a multistage, or a cascading-like effect. Rice’s team set out to show that each cycle in a cascade can be treated as an elementary unit, meaning that they can be reassembled in new configurations to form entirely novel pathways linking cellular inputs and outputs.

Previous research on using phosphorylation-based signaling for therapeutic purposes has focused on re-engineering pathways.

“This opens up the signaling circuit design space dramatically,” Caleb Bashor, assistant professor of bioengineering and biosciences and corresponding author on the study, said in a news release. “It turns out, phosphorylation cycles are not just interconnected but interconnectable … Our design strategy enabled us to engineer synthetic phosphorylation circuits that are not only highly tunable but that can also function in parallel with cells’ own processes without impacting their viability or growth rate.”

Bashor is the deputy director for the Rice Synthetic Biology Institute, which launched last year.

The Rice lab's sense-and-respond cellular circuit design is also innovative because phosphorylation occurs rapidly. Thus, the new circuits could potentially be programmed to respond to physiological events in minutes, compared to other methods, which take hours to activate.

Rice’s team successfully tested the circuits for sensitivity and their ability to respond to external signals, such as inflammatory issues. The researchers then used the framework to engineer a cellular circuit that can detect certain factors, control autoimmune flare-ups and reduce immunotherapy-associated toxicity.

“This work brings us a whole lot closer to being able to build ‘smart cells’ that can detect signs of disease and immediately release customizable treatments in response,” Xiaoyu Yang, a graduate student in the Systems, Synthetic and Physical Biology Ph.D. program at Rice who is the lead author on the study, said in a news release.

Ajo-Franklin, a professor of biosciences, bioengineering, chemical and biomolecular engineering and a Cancer Prevention and Research Institute of Texas Scholar, added “the Bashor lab’s work vaults us forward to a new frontier — controlling mammalian cells’ immediate response to change.”

Greentown Labs names new CEO to lead pioneering climate tech incubator

Transition News

Houston and Boston climate tech incubator Greentown Labs has named Georgina Campbell Flatter as the organization’s incoming CEO.

Flatter will transition to Greentown from her role as co-founder and executive director of TomorrowNow.org, a global nonprofit that studies and connects next-generation weather and climate technologies with communities most affected by climate change.

“We are at a transformational moment in the energy transition, with an unprecedented opportunity to drive solutions in energy production, sustainability, and climate resilience,” Flatter said in a news release. “Greentown Labs is, and has always been, a home for entrepreneurs and a powerhouse of collaboration and innovation.”

Previously, Flatter worked to launch TomorrowNow out of tomorrow.io, a Boston-based AI-powered weather intelligence and satellite technology company. The organization secured millions in climate philanthropy from partners, including the Gates Foundation, which helped deliver cutting-edge climate solutions to millions of African farmers weekly.

Flatter also spent 10 years at the Massachusetts Institute of Technology (MIT), where she was a senior lecturer and led global initiatives at the intersection of technology and social impact. Her research work includes time at Langer Lab and Sun Catalytix, an MIT – ARPA-E-funded spin-out that focused on energy storage solutions inspired by natural photosynthesis. Flatter is also an Acumen Rockefeller Global Food Systems Fellow and was closely involved with Greentown Labs when it was founded in Boston in 2011, according to the release.

“It’s rare to find an individual who has impressive climate and energy expertise along with nonprofit and entrepreneurial leadership—we’re fortunate Georgie brings all of this and more to Greentown Labs,” Bobby Tudor, Greentown Labs Board Chair and Chairman of the Houston Energy Transition Initiative, said in a news release.

Flatter will collaborate with Kevin Dutt, Greentown’s Interim CEO, and also continue to serve on Greentown’s Board of Directors, which was recently announced in December and contributed to a successful $4 million funding round. She’s also slated to speak at CERAWeek next month.

“In this next chapter, I’m excited to build on our entrepreneurial roots and the strength of our ever-growing communities in Boston and Houston,” Flatter added in a news release. “Together, we will unite entrepreneurs, partners, and resources to tackle frontier challenges and scale breakthrough technologies.”

Greentown also named Naheed Malik its new chief financial officer last month. The announcements come after Greentown’s former CEO and president, Kevin Knobloch, announced that he would step down in July 2024 after less than a year in the role.

---

This article originally appeared on our sister site, EnergyCapital.

Houston firm invests $150M in leading 'lab on a chip' medical diagnostics co.

fresh funds

Houston-based health technology investment firm Hamershlag Private Capital Management Limited (HPCM) announced a $150.15 million venture investment in Patho Care LLC.

Patho Care is a “lab on a chip” medical diagnostics company known for its noninvasive point-of-care testing platforms, such as its Raman spectroscopy-based platform.

Its digital point-of-care testing devices are programmable, mobile, and reusable and can detect current or future respiratory bacterial or viral infections. The company says the technology is more cost-effective and provides results faster than traditional diagnostic methods.

“Patho Care LLC is a distinguished leader in healthcare diagnostics through the utilization of a novel approach with spectroscopy and this investment aligns with HPCM’s strategy of partnering with high-potential companies in dynamic industries,” L. Mychal Jefferson, Chairman of Hamershlag, said in a news release.

The transaction was structured as an acquisition and recapitalization using newly issued common stock and cash, which will work through a newly formed entity, PathoCare Holdings Inc. The deal will also facilitate the repayment of Patho Care LLC's existing financial obligations and settle Patho Care’s outstanding notes, helping ensure the company’s financial readiness, according to the release.

The investment will help Patho Care LLC improve operational efficiencies, broaden its service offerings and continue to innovate in the diagnostic testing space. The companies hope the collaboration will help “unlock new growth opportunities while maintaining the company’s legacy of excellence in an emerging technology,” according to a news release.

“Our commitment to delivering transformative value through innovative investments underscores our confidence in Patho Care’s vision and capabilities,” Jefferson added.

View All Listings